MAPT and early-onset autosomal dominant Alzheimer disease: Moreover, preclinical research has shown neuroprotective effects by lowering tau hyperphosphorylation and amyloid-beta aggregation, therefore pointing to its potential for modifying the course of Alzheimer’s disease (Dan et al. 2024).